Kyntra Bio, Inc. (KYNB)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 176 | 235 | 141 | 47 | 30 | 6 | 5 | 7 |
| Operating profit | $m | -46 | -51 | ||||||
| Net profit | $m | -189 | -290 | -294 | -284 | -48 | 183 | 183 | - |
| EPS reported | $ | 45.37 | 58.19 | ||||||
| Operating cashflow per share | $ | -1.18 | -9.40 | ||||||
| Capex per share | $ | 0.01 | 0.00 | ||||||
| FCF per share | $ | -1.19 | -9.40 | ||||||
| Free cash flow | $m | -5 | -38 | ||||||
| Net debt | $m | -3 | -91 | ||||||
| Book value equity | $m | -30 | -8 | ||||||
| Book value per share | $ | -7.43 | -2.01 | ||||||
| Number of shares | m | 4.04 | 4.05 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 0.19 | 0.15 | ||||||
| P/B LTM | x | -1.18 | -4.36 | ||||||
| P/S LTM | x | 5.51 | 7.69 | ||||||
| P/FCF LTM | x | -7.38 | -0.93 | ||||||
| EV/EBITDA LTM | x | 0.22 | 0.13 | ||||||
| EV/Sales LTM | x | 11.36 | -4.79 | ||||||
| Earnings Yield LTM | % | +526.32% | +666.67% | ||||||
| FCF Yield | % | -13.56% | -107.22% | ||||||
| Quality | |||||||||
| ROE | % | -610.73% | -1136.07% | ||||||
| ROIC | % | -50.72% | -78.16% | ||||||
| Operating margin | % | -7.13% | -11.01% | ||||||
| Gross margin | % | +91.37% | +18.15% | ||||||
| FCF/Sales | % | -74.72% | -824.39% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -78.26% | -84.41% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | -100.00% | -100.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.06 | - | ||||||
| Net Debt/EBITDA | x | -0.65 | 0.54 | ||||||
| EBIT/Net interest | x | -5.24 | -5.47 | ||||||
| Net debt/market cap | % | +2.41% | 0.00% | ||||||
| Net debt/Equity | x | 0.11 | 11.21 | ||||||
| Gross debt/equity | x | -2.85 | -0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free